
Pfizer PFE
Annual report 2025
added 02-26-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
5.68 B |
Market Cap[1] |
$ 157 B |
EBITDA (LTM) |
$ 6.66 B |
P/E (LTM) |
11.3 |
P/S (LTM) |
2.5 |
EPS (LTM) |
2.44 |
Pfizer is a global pharmaceutical company that has been in operation for over 170 years. The company is headquartered in New York City and has a presence in over 150 countries worldwide. Pfizer's mission is to discover, develop, and deliver innovative medicines and vaccines that improve the lives of people around the world.
Pfizer has a diverse portfolio of products that address a range of health conditions, including cardiovascular disease, oncology, inflammation, immunology, and rare diseases. Some of the company's most well-known products include Lipitor, Viagra, and Lyrica.
In addition to developing new treatments, Pfizer is committed to improving access to healthcare for people in need. The company has established partnerships with governments, non-governmental organizations, and healthcare providers to expand access to its medicines and vaccines.
Pfizer is also dedicated to sustainability and reducing its environmental impact. The company has set ambitious goals to reduce greenhouse gas emissions, water consumption, and waste generation across its operations.
As a leading pharmaceutical company, Pfizer is constantly innovating and adapting to meet the changing needs of patients and healthcare providers. With a focus on research and development, access to healthcare, and sustainability, Pfizer is poised to continue making a positive impact on global health for years to come.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Amarin Corporation plc
AMRN
|
$ 14.67 | -0.07 % | $ 6.09 B | Nasdaq Global Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Cabaletta Bio
CABA
|
$ 2.82 | 1.44 % | $ 283 M | Nasdaq Global Select Market | ||
|
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.29 | -3.01 % | $ 329 M | Nasdaq Global Select Market | ||
|
CEL-SCI Corporation
CVM
|
$ 3.47 | -1.7 % | $ 221 M | NYSE American,SPB | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Denali Therapeutics
DNLI
|
$ 19.74 | -12.17 % | $ 3.25 B | Nasdaq Global Select Market,SPB | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | ||
|
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.09 | -9.17 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Enochian Biosciences
ENOB
|
- | - | $ 40.5 M | Nasdaq Capital Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Equillium
EQ
|
$ 2.06 | - | $ 118 M | Nasdaq Global Market | ||
|
Esperion Therapeutics
ESPR
|
$ 2.85 | 3.26 % | $ 592 M | Nasdaq Global Market,SPB | ||
|
Eton Pharmaceuticals
ETON
|
$ 23.45 | -1.64 % | $ 631 M | Nasdaq Global Market | ||
|
China SXT Pharmaceuticals
SXTC
|
$ 1.32 | -5.2 % | $ 1.88 M | Nasdaq Global Select Market | ||
|
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 47.55 | 0.98 % | $ 4.28 B | Nasdaq Global Market,SPB | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.45 | -1.77 % | $ 853 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.